Open AccessFive Years Follow-up of Riboflavin/Ultraviolet A (370 nm) Corneal Collagen Cross-linking to Halt the Progression of Keratoconus
Author(s) -
PS David O’Brart,
Parul Patel,
Naomi A. L. O'Brart
Publication year - 2014
Publication title -
international journal of keratoconus and ectatic corneal diseases
Language(s) - English
Resource type - Journals
eISSN - 2277-4203
pISSN - 2277-3800
DOI - 10.5005/jp-journals-10025-1081
Subject(s) - keratoconus , dioptre , medicine , ophthalmology , coma (optics) , astigmatism , corneal collagen cross linking , cornea , visual acuity , optics , physics
Aims To determine the long-term efficacy and safety of riboflavin/ultraviolet a corneal cross-linking (CXL) to halt the progression of keratoconus. Materials and methods Thirty-five patients (35 eyes) who had undergone CXL with epithelial removal 5 or more years previously were examined. Results At 5 years, mean spherical equivalent (SEQ) increased by 0.78 diopters (D) (p 1 line of CDVA. Eight untreated fellow eyes progressed during the follow-up period and underwent CXL. Conclusions Corneal cross-linking is an effective treatment to halt the progression of keratoconus at 5 years, with no sight-threatening complications. Improvements in topographic and wave-front indices present at 1 year continue to improve at 5 years. How to cite this article O’Brart PSD, Patel P, O’Brart NA. Five Years Follow-up of Riboflavin/Ultraviolet A (370 nm) Corneal Collagen Cross-linking to Halt the Progression of Keratoconus. Int J Kerat Ect Cor Dis 2014;3(2):63-68.